Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 3 |
2010 | 2 |
2011 | 3 |
2012 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Cancer microRNAs: from subtype profiling to predictors of response to therapy.
Trends Mol Med. 2011 May;17(5):235-43. doi: 10.1016/j.molmed.2011.01.008. Epub 2011 Feb 25.
Trends Mol Med. 2011.
PMID: 21354374
Free PMC article.
Review.
MicroRNAs: tools for cancer diagnostics.
Paranjape T, Slack FJ, Weidhaas JB.
Paranjape T, et al.
Gut. 2009 Nov;58(11):1546-54. doi: 10.1136/gut.2009.179531.
Gut. 2009.
PMID: 19834118
Free PMC article.
Item in Clipboard
Regression of murine lung tumors by the let-7 microRNA.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ.
Trang P, et al.
Oncogene. 2010 Mar 18;29(11):1580-7. doi: 10.1038/onc.2009.445. Epub 2009 Dec 7.
Oncogene. 2010.
PMID: 19966857
Free PMC article.
Item in Clipboard
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.
Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ.
Kato M, et al.
Oncogene. 2009 Jun 25;28(25):2419-24. doi: 10.1038/onc.2009.106. Epub 2009 May 4.
Oncogene. 2009.
PMID: 19421141
Free PMC article.
Item in Clipboard
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB.
Pelletier C, et al.
Cell Cycle. 2011 Jan 1;10(1):90-9. doi: 10.4161/cc.10.1.14359. Epub 2011 Jan 1.
Cell Cycle. 2011.
PMID: 21191178
Free PMC article.
Item in Clipboard
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.
Ratner ES, et al.
Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.
Oncogene. 2012.
PMID: 22139083
Free PMC article.
Item in Clipboard
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.
Ratner E, et al.
Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.
Cancer Res. 2010.
PMID: 20647319
Free PMC article.
Item in Clipboard
Cite
Cite